{"id":"NCT00963235","sponsor":"Pfizer","briefTitle":"Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS","officialTitle":"A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11","primaryCompletion":"2012-05","completion":"2012-05","firstPosted":"2009-08-21","resultsPosted":"2013-06-10","lastUpdate":"2013-06-10"},"enrollment":331,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["HIV Infections","Pneumococcal Infections"],"interventions":[{"type":"BIOLOGICAL","name":"13-valent pneumococcal conjugate vaccine","otherNames":["13vPnC"]},{"type":"PROCEDURE","name":"Blood draw","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"The study will evaluate the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC) in HIV-infected subjects 18 years of age or older who have been previously immunized with at least one dose of 23-valent pneumococcal polysaccharide vaccine (23vPS). All subjects will receive 3 doses of 13vPnC, with each study vaccine dose given approximately 6 months apart.","primaryOutcome":{"measure":"Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After Dose 2 of 13vPnC to 1 Month After Dose 3 of 13vPnC","timeFrame":"1 month post-dose 2, 1 month post-dose 3","effectByArm":[{"arm":"13vPnC","deltaMin":0.94,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":21},"locations":{"siteCount":15,"countries":["United States"]},"refs":{"pmids":["25395187"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=6115A1-3017&StudyName=Safety%20%26%20Immunogenicity%20of%2013vPnC%20in%20HIV-Infected%20Subjects%20Aged%2018%20or%20Older%20Who%20Were%20Previously%20Immunized%20with%2023vPS"]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":329},"commonTop":["Pain (Any)","Pain (Mild)","New generalized muscle pain (Any)","New generalized muscle pain (Mild)","Fatigue (Any)"]}}